{"url_path":"/sec/prax/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1689548/0001689548-26-000049-index.html","accession_number":"0001689548-26-000049","cik":"0001689548","ticker":"PRAX","issuer_name":"Praxis Precision Medicines, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1689548/0001689548-26-000049-index.html","primary_entity_key":"0001689548","primary_entity_name":"Praxis Precision Medicines, Inc."},"word_count":53,"has_tables":true,"body_markdown":"Item 2.02. Results of Operations and Financial Condition.\n\nOn May 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release containing these announcements is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”)."}